|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-05
|
$1,806,651
|
$1,806,651
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas
|
4R00CA160775-02
|
$233,998
|
$233,998
|
Ahmed, Atique
|
UNIVERSITY OF CHICAGO
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$757,277
|
$113,592
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
|
5P01CA066726-16
|
$1,111,842
|
$311,316
|
Albelda, Steven
|
UNIVERSITY OF PENNSYLVANIA
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-04
|
$386,926
|
$386,926
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-29
|
$638,503
|
$638,503
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB
|
5R01CA073756-14
|
$237,227
|
$237,227
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-04
|
$2,716,765
|
$2,363,586
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Platform for MR-Guided Neurotherapeutic Drug Delivery
|
1R43CA177205-01A1
|
$216,225
|
$108,113
|
Barker, Edward
|
INSERT, INC.
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
4R00CA139006-03
|
$234,059
|
$234,059
|
Bartholomeusz, Chandra
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-14S1
|
$31,250
|
$3,750
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-14
|
$2,082,690
|
$249,923
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-04
|
$292,312
|
$96,463
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE: Brain Tumor SPORE Grant
|
2P50CA097257-11A1
|
$2,150,500
|
$107,525
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-15
|
$596,700
|
$119,340
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CAN RES CTR
|
|
Pediatric Oncology Research Training Program
|
5T32CA009351-35
|
$239,826
|
$47,965
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CAN RES CTR
|
|
Image-guided Prodrug and siRNA Targeting of Cancer
|
5R01CA138515-05
|
$310,286
|
$310,286
|
Bhujwalla, Zaver
|
JOHNS HOPKINS UNIVERSITY
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-02
|
$3,054,903
|
$641,530
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-12
|
$320,646
|
$32,065
|
Bland, Kirby
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Mechanisms of Viral Fusion and Inactivation
|
ZIA BC 008303
|
$228,937
|
$22,894
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Lipid-based Nanocapsules and Triggered Chemotherapy
|
ZIA BC 010652
|
$343,405
|
$103,022
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-10
|
$262,036
|
$262,036
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-04
|
$292,312
|
$96,463
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-05
|
$358,720
|
$358,720
|
Brentjens, Renier
|
SLOAN-KETTERING INST CAN RES
|
|
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer
|
5K08CA142904-04
|
$173,448
|
$173,448
|
Camp, Ernest
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
1R01CA166590-01A1
|
$317,475
|
$158,738
|
Cao, Lei
|
OHIO STATE UNIVERSITY
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
5R01CA151391-04
|
$325,422
|
$162,711
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
SPORE in Prostate Cancer
|
3P50CA090386-10S1
|
$48,038
|
$3,363
|
Catalona, William
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
SPORE in Prostate Cancer
|
5P50CA090386-10
|
$2,150,501
|
$150,535
|
Catalona, William
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Therapeutic vaccination against genital HPV infection
|
1R43CA174436-01A1
|
$288,194
|
$288,194
|
Chang, Yung
|
PAPIVAX, LLC
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-05
|
$619,594
|
$154,899
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
Aspects of MUC13 Mucin in Cancer
|
5R01CA142736-04
|
|
$0
|
Chauhan, Subhash
|
SANFORD RESEARCH/USD
|
|
Aspects of MUC13 Mucin in Cancer
|
7R01CA142736-05
|
$295,230
|
$147,615
|
Chauhan, Subhash
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
Overcoming Immune Suppression to Enhance Tumor Vaccine Efficacy
|
5R01CA090427-10
|
$297,506
|
$297,506
|
Chen, Si-Yi
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Genetic Therapy for Fanconi Anemia
|
5R01CA155294-03
|
$300,377
|
$300,377
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
IMAGING T CELLS BY POSITRON EMISSION TOMOGRAPHY
|
5R01CA163587-02
|
$575,114
|
$287,557
|
COOPER, LAURENCE
|
UT MD ANDERSON CANCER CTR
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,237,347
|
$24,747
|
Cooper, Julia
|
CCR (NCI)
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,133,603
|
$283,401
|
Court, Donald
|
CCR (NCI)
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-03
|
$449,047
|
$449,047
|
Curiel, David
|
WASHINGTON UNIVERSITY
|
|
Antibody-mediated Gene Therapy for the Treatment of Cancer
|
5K01CA138559-05
|
$142,677
|
$71,339
|
Daniels, Tracy
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Anti-Cancer RNA Nanoconjugates
|
2R15CA139390-02
|
$398,649
|
$398,649
|
DELONG, ROBERT
|
MISSOURI STATE UNIVERSITY
|
|
Development of Pro-SELEX Aptamer Selection Platform
|
5R44CA150490-03
|
$703,373
|
$351,687
|
DEMPSEY, PAUL
|
CYNVENIO BIOSYSTEMS, INC.
|
|
Carolina Center of Cancer Nanotechnology Excellence
|
5U54CA151652-04
|
$2,058,365
|
$226,420
|
DeSimone, Joseph
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
|
1R21CA174306-01A1
|
$182,700
|
$91,350
|
Diamond, Don
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-12
|
$1,899,920
|
$189,992
|
DINNEY, COLIN
|
UT MD ANDERSON CANCER CTR
|
|
Cell Production Facility Core
|
ZIC BC 011020
|
$697,119
|
$348,559
|
Dudley, Mark
|
CCR (NCI)
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$670,870
|
$670,870
|
Feldman, Steven
|
CCR (NCI)
|
|
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
|
3R21CA153165-02S1
|
$62,961
|
$62,961
|
FIGUEIREDO, MARXA
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
|
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
|
5R21CA153165-02
|
$186,664
|
$186,664
|
FIGUEIREDO, MARXA
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIA BC 011219
|
$224,566
|
$112,283
|
Fowler, Daniel
|
CCR (NCI)
|
Total relevant funding to Gene Therapy for this search: $51,944,422
|